One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer
Positron emission tomography (PET) imaging is a useful method to evaluate in situ estrogen receptor (ER) status for the early diagnosis of breast cancer and optimization of the appropriate treatment strategy. The 18F-labeled estradiol derivative has been successfully used to clinically assess the ER...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi-Wiley
2018-01-01
|
Series: | Contrast Media & Molecular Imaging |
Online Access: | http://dx.doi.org/10.1155/2018/5362329 |
id |
doaj-e3c9ed4089ab4416afa7b0f8e947be05 |
---|---|
record_format |
Article |
spelling |
doaj-e3c9ed4089ab4416afa7b0f8e947be052020-11-25T01:14:20ZengHindawi-WileyContrast Media & Molecular Imaging1555-43091555-43172018-01-01201810.1155/2018/53623295362329One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast CancerHongbo Huang0Ke Li1Gaochao Lv2Guiqing Liu3Xueyu Zhao4Qingzhu Liu5Shanshan Wang6Xi Li7Ling Qiu8Jianguo Lin9Key Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaPositron emission tomography (PET) imaging is a useful method to evaluate in situ estrogen receptor (ER) status for the early diagnosis of breast cancer and optimization of the appropriate treatment strategy. The 18F-labeled estradiol derivative has been successfully used to clinically assess the ER level of breast cancer. In order to simplify the radiosynthesis process, one-step 18F-19F isotope exchange reaction was employed for the 18F-fluorination of the tracer of [18F]AmBF3-TEG-ES. The radiotracer was obtained with the radiochemical yield (RCY) of ~61% and the radiochemical purity (RCP) of >98% within 40 min. Cell uptake and blocking assays indicated that the tracer could selectively accumulate in the ER-positive human breast cancer cell lines MCF-7 and T47D. In vivo PET imaging on the MCF-7 tumor-bearing mice showed relatively high tumor uptake (1.4~2.3 %D/g) and tumor/muscle uptake ratio (4~6). These results indicated that the tracer is a promising PET imaging agent for ER-positive breast cancers.http://dx.doi.org/10.1155/2018/5362329 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hongbo Huang Ke Li Gaochao Lv Guiqing Liu Xueyu Zhao Qingzhu Liu Shanshan Wang Xi Li Ling Qiu Jianguo Lin |
spellingShingle |
Hongbo Huang Ke Li Gaochao Lv Guiqing Liu Xueyu Zhao Qingzhu Liu Shanshan Wang Xi Li Ling Qiu Jianguo Lin One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer Contrast Media & Molecular Imaging |
author_facet |
Hongbo Huang Ke Li Gaochao Lv Guiqing Liu Xueyu Zhao Qingzhu Liu Shanshan Wang Xi Li Ling Qiu Jianguo Lin |
author_sort |
Hongbo Huang |
title |
One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer |
title_short |
One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer |
title_full |
One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer |
title_fullStr |
One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer |
title_full_unstemmed |
One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer |
title_sort |
one-step 18f-labeling of estradiol derivative for pet imaging of breast cancer |
publisher |
Hindawi-Wiley |
series |
Contrast Media & Molecular Imaging |
issn |
1555-4309 1555-4317 |
publishDate |
2018-01-01 |
description |
Positron emission tomography (PET) imaging is a useful method to evaluate in situ estrogen receptor (ER) status for the early diagnosis of breast cancer and optimization of the appropriate treatment strategy. The 18F-labeled estradiol derivative has been successfully used to clinically assess the ER level of breast cancer. In order to simplify the radiosynthesis process, one-step 18F-19F isotope exchange reaction was employed for the 18F-fluorination of the tracer of [18F]AmBF3-TEG-ES. The radiotracer was obtained with the radiochemical yield (RCY) of ~61% and the radiochemical purity (RCP) of >98% within 40 min. Cell uptake and blocking assays indicated that the tracer could selectively accumulate in the ER-positive human breast cancer cell lines MCF-7 and T47D. In vivo PET imaging on the MCF-7 tumor-bearing mice showed relatively high tumor uptake (1.4~2.3 %D/g) and tumor/muscle uptake ratio (4~6). These results indicated that the tracer is a promising PET imaging agent for ER-positive breast cancers. |
url |
http://dx.doi.org/10.1155/2018/5362329 |
work_keys_str_mv |
AT hongbohuang onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT keli onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT gaochaolv onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT guiqingliu onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT xueyuzhao onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT qingzhuliu onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT shanshanwang onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT xili onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT lingqiu onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer AT jianguolin onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer |
_version_ |
1725157327881895936 |